Tailored drug combo tested to better fight common breast cancer
NCT ID NCT06650748
Summary
This study aims to see if a more personalized approach improves treatment for early-stage, hormone-positive breast cancer. It will test if adding a targeted drug called a CDK4/6 inhibitor to standard hormone therapy works better for patients identified as having a higher risk of cancer returning. The goal is to control the disease more effectively before surgery, potentially leading to better long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.